Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2023 | 804 | 2.250 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 285 | 1.180 |
Why?
|
| Cancer Survivors | 5 | 2022 | 187 | 0.950 |
Why?
|
| Lymphoma | 2 | 2023 | 322 | 0.860 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 69 | 0.830 |
Why?
|
| Organ Transplantation | 1 | 2023 | 163 | 0.740 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.720 |
Why?
|
| Hematologic Diseases | 1 | 2021 | 78 | 0.700 |
Why?
|
| Obesity | 4 | 2020 | 2229 | 0.700 |
Why?
|
| Survivors | 6 | 2020 | 345 | 0.620 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 2599 | 0.600 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 96 | 0.590 |
Why?
|
| Overweight | 2 | 2020 | 358 | 0.580 |
Why?
|
| Genetic Markers | 3 | 2015 | 610 | 0.550 |
Why?
|
| Neoplasms | 7 | 2022 | 2767 | 0.530 |
Why?
|
| Body Mass Index | 3 | 2020 | 1543 | 0.520 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 224 | 0.500 |
Why?
|
| Folic Acid | 3 | 2013 | 292 | 0.490 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 30 | 0.390 |
Why?
|
| Child | 29 | 2023 | 24205 | 0.390 |
Why?
|
| Hematology | 1 | 2012 | 37 | 0.380 |
Why?
|
| Conscious Sedation | 1 | 2012 | 62 | 0.380 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 810 | 0.370 |
Why?
|
| Membrane Proteins | 2 | 2015 | 1525 | 0.360 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 185 | 0.350 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 209 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2015 | 3098 | 0.330 |
Why?
|
| Risk Factors | 11 | 2023 | 10001 | 0.330 |
Why?
|
| Genotype | 5 | 2017 | 2547 | 0.320 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3007 | 0.310 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 619 | 0.300 |
Why?
|
| Cognition Disorders | 2 | 2011 | 554 | 0.290 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 645 | 0.280 |
Why?
|
| Quality Improvement | 1 | 2012 | 624 | 0.260 |
Why?
|
| Child, Preschool | 17 | 2021 | 13859 | 0.240 |
Why?
|
| Humans | 34 | 2023 | 123177 | 0.230 |
Why?
|
| Pediatrics | 2 | 2019 | 1139 | 0.220 |
Why?
|
| Methotrexate | 2 | 2023 | 342 | 0.220 |
Why?
|
| DNA Methylation | 2 | 2020 | 991 | 0.210 |
Why?
|
| Male | 22 | 2021 | 60017 | 0.210 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2013 | 21 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2011 | 1677 | 0.210 |
Why?
|
| Liver Transplantation | 1 | 2011 | 1013 | 0.210 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 43 | 0.200 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2021 | 10 | 0.190 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 29 | 0.190 |
Why?
|
| Positron-Emission Tomography | 2 | 2013 | 287 | 0.180 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2011 | 70 | 0.180 |
Why?
|
| Pharyngitis | 1 | 2021 | 31 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 136 | 0.180 |
Why?
|
| Female | 22 | 2021 | 65423 | 0.180 |
Why?
|
| Mycoses | 1 | 2021 | 117 | 0.170 |
Why?
|
| Age Factors | 3 | 2021 | 2801 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2023 | 15979 | 0.170 |
Why?
|
| Adiposity | 1 | 2020 | 191 | 0.160 |
Why?
|
| Hemochromatosis Protein | 2 | 2015 | 22 | 0.160 |
Why?
|
| Adolescent | 14 | 2021 | 19084 | 0.160 |
Why?
|
| Genome-Wide Association Study | 3 | 2022 | 1650 | 0.160 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 138 | 0.150 |
Why?
|
| Francisella | 1 | 2017 | 4 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 286 | 0.150 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2019 | 162 | 0.150 |
Why?
|
| Tularemia | 1 | 2017 | 13 | 0.150 |
Why?
|
| Attention | 1 | 2019 | 194 | 0.150 |
Why?
|
| Transplantation Conditioning | 1 | 2019 | 323 | 0.140 |
Why?
|
| Infant | 8 | 2021 | 12321 | 0.140 |
Why?
|
| Weight Gain | 1 | 2019 | 401 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 145 | 0.130 |
Why?
|
| Lymph Nodes | 1 | 2017 | 375 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2015 | 3260 | 0.130 |
Why?
|
| Radiation Dosage | 2 | 2013 | 132 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2015 | 32 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 2043 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2015 | 65 | 0.120 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2014 | 5 | 0.120 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 61 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 850 | 0.120 |
Why?
|
| Young Adult | 4 | 2021 | 8866 | 0.120 |
Why?
|
| Health Services | 1 | 2014 | 71 | 0.120 |
Why?
|
| Birth Weight | 1 | 2015 | 336 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1105 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 515 | 0.110 |
Why?
|
| Gene-Environment Interaction | 1 | 2013 | 120 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 420 | 0.100 |
Why?
|
| Adult | 6 | 2020 | 29033 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 135 | 0.100 |
Why?
|
| Texas | 1 | 2021 | 3548 | 0.100 |
Why?
|
| Algorithms | 2 | 2021 | 1597 | 0.100 |
Why?
|
| Lymphoma, B-Cell | 1 | 2013 | 135 | 0.100 |
Why?
|
| Burkitt Lymphoma | 1 | 2013 | 145 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 614 | 0.100 |
Why?
|
| Models, Genetic | 2 | 2014 | 767 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 2108 | 0.100 |
Why?
|
| Gestational Age | 1 | 2015 | 1121 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 1194 | 0.090 |
Why?
|
| Premature Birth | 1 | 2015 | 380 | 0.090 |
Why?
|
| Bayes Theorem | 2 | 2023 | 278 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 180 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 3377 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2020 | 6028 | 0.080 |
Why?
|
| Prevalence | 1 | 2016 | 2403 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 293 | 0.080 |
Why?
|
| Herpesvirus 4, Human | 2 | 2022 | 659 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 215 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2017 | 8089 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1114 | 0.070 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1431 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2008 | 213 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 1230 | 0.070 |
Why?
|
| Hospitalization | 1 | 2014 | 1733 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 1259 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2021 | 762 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2019 | 12102 | 0.060 |
Why?
|
| Switzerland | 1 | 2023 | 18 | 0.050 |
Why?
|
| Recurrence | 2 | 2019 | 1420 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 1861 | 0.050 |
Why?
|
| Pregnancy | 1 | 2015 | 7124 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2023 | 167 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2011 | 3332 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 133 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 98 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 104 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 225 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 380 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 533 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 1216 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 172 | 0.040 |
Why?
|
| Headache | 1 | 2021 | 107 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 1245 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2021 | 293 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2020 | 271 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2019 | 216 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 296 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 188 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 657 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2017 | 92 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1390 | 0.040 |
Why?
|
| Genes, Bacterial | 1 | 2017 | 208 | 0.030 |
Why?
|
| Genome, Bacterial | 1 | 2017 | 184 | 0.030 |
Why?
|
| Virulence Factors | 1 | 2017 | 172 | 0.030 |
Why?
|
| Whole Genome Sequencing | 1 | 2017 | 286 | 0.030 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 222 | 0.030 |
Why?
|
| DNA, Bacterial | 1 | 2017 | 481 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 921 | 0.030 |
Why?
|
| Apoptosis | 1 | 2022 | 1783 | 0.030 |
Why?
|
| Monosomy | 1 | 2015 | 24 | 0.030 |
Why?
|
| Hospital Records | 1 | 2014 | 8 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 997 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 671 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 330 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2017 | 468 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1418 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 757 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2014 | 243 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 101 | 0.030 |
Why?
|
| Remission Induction | 1 | 2013 | 300 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 156 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 338 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2014 | 715 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 6201 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 1760 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2017 | 1480 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1684 | 0.020 |
Why?
|
| Anthracyclines | 1 | 2010 | 42 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2013 | 471 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1607 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 280 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2010 | 139 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 4225 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 370 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 5047 | 0.010 |
Why?
|
| Prognosis | 1 | 2013 | 4508 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 4708 | 0.010 |
Why?
|
| Mass Screening | 1 | 2008 | 790 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 2851 | 0.010 |
Why?
|
| United States | 1 | 2014 | 10618 | 0.010 |
Why?
|